UBS maintains Aramark at Buy, raises price target to $68 from $65

UBS kept its Buy rating on Aramark and increased its price target to $68 from $65, suggesting a 22.8% upside from the recent close. Other analysts have set targets between $61 and $65 for the company.

Original reporting
Published Nov 17, 2026, 2:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UBS maintains Aramark at Buy, raises price target to $68 from $65 — source image
Decision brief

The 30-second read

$ARMKBullishLow
01

Why it matters

This is a valuation update rather than a fundamental disclosure, so it mainly affects positioning and sentiment around the stock’s expected value.

02

Market read

Traders may use the target raise as a near-term sentiment input, but it is unlikely to be a standalone driver without accompanying company news.

03

What to watch

Traders may focus more on consensus revisions and near-term earnings/guidance than on a single-bank target change; the article also notes recent targets range only up to $65, implying the raise may be incremental versus peers.

Relevance 4/10Novelty 3/10Timing: today, as the UBS price-target update circulates in the analyst tape

Background

The piece summarizes UBS’s latest analyst note on Aramark, including a maintained Buy rating and an increased price target.

Company-level read

Ticker impact

$ARMKBullishMedium confidence
Context

UBS maintained Aramark at Buy and raised its price target to $68 from $65, signaling a fresh valuation view for ARAMARK shares.

Expected impact

Mild upward bias as traders price in the higher UBS target, though broader impact is likely limited because it is an analyst action rather than a new company disclosure.

Evidence & confidence

The article provides a specific, incremental price-target change (from $65 to $68) tied to a maintained Buy rating, but it does not include new fundamentals, guidance, or earnings.

Market effects

Could modestly buoy sentiment for contract foodservice and facility services peers if the market treats the target raise as a read-through on demand/margins.

No clear regional spillover beyond US-listed analyst sentiment.

Limited global relevance; this is a single-name sell-side valuation update.

Counterpoint

A higher price target without new company-specific catalysts may have limited follow-through, especially if other analysts’ targets cluster below the new level.

Key entities

  • Aramark

    US contract foodservice and facilities services company covered by UBS in the article.

  • UBS

    Sell-side firm maintaining a Buy rating and raising the price target.

Related articles

$ARMKMed

Aramark Q4 2026 Earnings Call Summary

Aramark reported record annualized gross new client wins of $1.9 billion, a 97% client retention rate, and launched Aramark Nexus. The company reduced its leverage ratio to 2.7x, enabling a $1 billion share repurchase program and a 17% dividend increase. For fiscal 2027, Aramark projects $500 million in revenue from Nexus, 9-10% organic revenue growth, and 15-19% adjusted operating income growth. Management highlighted supply chain efficiencies and mitigating inflation impacts.

$ARMKMed

Aramark (ARMK) Q4 2026 Earnings Call Transcript

Aramark (ARMK) reported Q4 2026 revenue of $20.1B, up 10% YoY, with U.S. and international organic growth of 8% and 12%, respectively. Adjusted EPS grew 21% on a constant currency basis. The company announced a $1B share repurchase program and a 17% dividend increase. Key segments like Collegiate Hospitality and Healthcare Plus drove growth. Aramark Nexus contributed 1% to organic revenue growth, scaling premium hospitality services.

$ARMKHigh

Why is Aramark stock sliding today?

Aramark (ARMK) shares fell 4.7% pre-market after reporting Q4 2026 results that missed estimates, with adjusted EPS at $0.71 vs. $0.75 and revenue at $5.29B vs. $5.30B. The company's fiscal 2027 guidance also fell short of expectations. Despite a 25% YoY EPS increase and 4.8% revenue growth, the stock dropped due to broader market pressures and the earnings miss.